04 September 2014 : Original article
Aberrant Methylation of CDH13 is a Potential Biomarker for Predicting the Recurrence and Progression of Non Muscle Invasive Bladder Cancer
DOI: 10.12659/MSM.892130
Med Sci Monit 2014; 20:1572-1577
HTML version available soon